BLAINJECTIONINJECTABLE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PAVBLU (aflibercept-ayyh) by Amgen is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2024.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAVBLU (aflibercept-ayyh) is a fusion protein and VEGF inhibitor approved by the FDA in August 2024 as a biosimilar to EYLEA. It binds vascular endothelial growth factor to suppress angiogenesis and is indicated for retinal diseases driven by abnormal blood vessel growth.
Growth
Early-stage biosimilar with significant upside; likely building commercial infrastructure and field team to capture share from the $74M+ EYLEA franchise.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PAVBLU represents a high-impact commercial launch for Amgen's ophthalmology franchise, with career growth in sales, pricing strategy, and market access roles. Early-stage biosimilar approvals typically demand hands-on leadership and rapid team scaling to capture market share before competitive dynamics shift.
Director
Worked on PAVBLU at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.